Riik: Lõuna-Aafrika Vabariik
keel: inglise
Allikas: South African Health Products Regulatory Authority (SAHPRA)
Lennon
INDICATIONS [/za_1267.html#1] [/za_1267.html#1] [/za_1267.html#1] CONTRA-INDICATIONS [/za_1267.html#1] [/za_1267.html#1] DOSAGE [/za_1267.html#1] [/za_1267.html#1] SIDE-EFFECTS [/za_1267.html#1] [/za_1267.html#1] [/za_1267.html#1] PREGNANCY [/za_1267.html#1] [/za_1267.html#1] OVERDOSE [/za_1267.html#1] IDENTIFICATION [/za_1267.html#1] [/za_1267.html#1] PATIENT INFORMATION HYPERPHEN®-10 TABLETS HYPERPHEN®-50 TABLETS SCHEDULING STATUS: S3 PROPRIETARY NAME: (and dosage form) HYPERPHEN ® -10 TABLETS HYPERPHEN ® -50 TABLETS COMPOSITION: Tablets containing a) 10 mg HYDRALLAZINE Hydrochloride b) 50 mg Hydrallazine Hydrochloride. PHARMACOLOGICAL CLASSIFICATION: A7.1.3 Other hypotensives. PHARMACOLOGICAL ACTION: The major action of hydrallazine is direct relaxation of vascular smooth muscle with a greater effect on arterioles than on veins. Therefore in adequate doses it decreases arterial blood pressure, diastolic often more than systolic, and peripheral vascular resistance, and increases heart rate, stroke volume, and cardiac output. The preferential dilatation of arterioles, minimizes postural hypotension and promotes the increase in cardiac output. The latter may limit the reduction in mean blood pressure produced by the drug. The peripheral vasodilatation is widespread but not uniform. Glomerular filtration, renal tubular function, and urine volume are not consistently affected; however, in common with many other hypertensive agents, hydrallazine can produce sodium retention and decreased urine volume. Hydrallazine usually increases plasma renin activity. Vascular resistance in the cutaneous and muscle beds may decrease, but this is usually in parallel with the fall in blood pressure and blood flow does not increase. Effects of hydrallazine on organs other than those of t Lugege kogu dokumenti